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Introduction {#sec1}
============

The emergence and spread of a novel coronavirus, SARS-CoV-2, causing severe respiratory disease (COVID-19) has now led to a pandemic with a major impact on global health, the economy, and societal behavior ([@bib24], [@bib30], [@bib45]). By March 15, 2020, more than 150,000 confirmed cases of SARS-CoV-2 had been reported, with close to 6,000 deaths. Now, a month later, those numbers have swelled to 2.4 million cases globally, with more than 165,000 deaths. Phylogenetic analysis has demonstrated that SARS-CoV-2 and SARS-CoV, a coronavirus that also caused a global outbreak in 2003, are closely related phylogenetically, with genomic nucleotide sequence identity of \~80% ([@bib39], [@bib44]). Moreover, both viruses use the angiotensin-converting enzyme 2 (ACE2) as the receptor for cell entry and infection ([@bib13], [@bib17], [@bib18], [@bib44]).

The spike glycoprotein (S) on the surface of coronaviruses is essential for virus entry through binding to the ACE2 receptor and for viral fusion with the host cell. The S protein forms a homotrimer in which each protomer is composed of two subunits, S1 and S2 ([Figure 1](#fig1){ref-type="fig"} A). Binding of the receptor-binding domain (RBD) in the S1 subunit to the ACE2 receptor triggers a conformational change in the S protein that subsequently initiates membrane fusion events with the host cell. The RBD is also a primary target of the antibody response in humoral immunity and is believed to be the major protective antigenic region in SARS-CoV ([@bib6]). The prefusion structure of the S protein of SARS-CoV-2 was recently determined by cryogenic electron microscopy (cryo-EM) ([@bib37]) and revealed an overall structural similarity to that of SARS-CoV. However, most monoclonal antibodies tested to date that target the RBD of SARS-CoV have failed to bind to the RBD of SARS-CoV-2 ([@bib27], [@bib37]), suggesting that the antigenicity of these two viruses to the RBD is quite distinct. So far, data have not yet been reported from polyclonal human sera from patients to evaluate the antibody response elicited by SARS-CoV-2 infection and to determine whether cross-reactive antibody responses between SARS-CoV-2 and SARS-CoV can be generated. In this study, we examined the antibody responses in 15 patients from Hong Kong who were infected by SARS-CoV-2, and seven who were infected by SARS-CoV. Mice infected or immunized with SARS-CoV-2 or SARS-CoV were also used to investigate cross-reactivity of antibody responses between SARS-CoV-2 and SARS-CoV.Figure 1Human Serological Responses to SARS-CoV-2(A) Schematic diagram of the SARS-CoV-2 spike protein. Locations of secretion signal peptide (SP), N-terminal domain (NTD), receptor-binding domain (RBD), S1/S2 cleavage site, S2′ cleavage site, fusion peptide (FP), heptad repeat 1 (HR1), heptad repeat 2 (HR2), transmembrane domain (TM), and cytoplasmic domain (CP) are indicated. Regions corresponding to the S1, S2, S2′ subunits, and ectodomain are also indicated.(B and C) Binding of plasma from healthy donors and SARS-CoV-2-infected patients to SARS-CoV-2 spike protein, SARS-CoV-2 RBD protein, SARS-CoV-2 S2 subunit, SARS-CoV spike protein, and SARS-CoV RBD protein were measured by ELISA (B). The mean OD~450~ values calculated after testing each plasma sample in triplicate are shown. (C) Neutralization activities of plasma from SARS-CoV-2-infected patients to SARS-CoV-2 and SARS-CoV viruses were measured. Dashed line represents the lower detection limit. Black lines indicate means ± SD. (B and C) Grey, plasma samples from healthy donors; orange, plasma samples from SARS-CoV-2-infected patients; blue, plasma samples from SARS-CoV-infected patients. The value from each dot in the figure was taken by the means of two replicates in the same assay.

Results {#sec2}
=======

Patient Samples Show Cross-Reactivity in Binding {#sec2.1}
------------------------------------------------

Fifteen heparin-anticoagulated plasma samples (from day 2 to 22 after symptom onset) from SARS-CoV-2-infected patients were analyzed ([Table S1](#mmc1){ref-type="supplementary-material"}), with plasma samples from healthy donors collected from the Hong Kong Red Cross as controls. Binding of plasma to the trimeric S ectodomain and monomeric RBD of both SARS-CoV-2 and SARS-CoV ([Figure S2](#mmc1){ref-type="supplementary-material"}; see [STAR Methods](#sec4){ref-type="sec"}) was measured by ELISA using anti-immunoglobulin G (anti-IgG) secondary antibodies ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}). RBD on the trimeric S protein is less exposed than the monomeric RBD, especially when it adopts a "down" conformation ([@bib15], [@bib32], [@bib37], [@bib42]), and may hinder binding of some RBD-targeted antibodies. Indeed, conformational rearrangements are required to bind the ACE2 receptor where the RBD adopts an "up," versus a "down," conformation ([@bib10], [@bib25], [@bib40]). Therefore, in the following results, we avoid making a comparison between the binding signals in S protein ELISA and that in RBD ELISA.

When compared with the plasma from healthy donors, plasma from patients from day 11 post-symptom onward have significant binding to the S ectodomain (p \< 2e−16, two-tailed t test) and RBD (p = 2e−13, two-tailed t test) of SARS-CoV-2. The observation that none of the plasma from patients on or before day 11 post-symptom binds to the SARS-CoV-2 S ectodomain and RBD is consistent with a previous study that showed seroconversion in SARS-CoV-2-infected patients can be as late as 14 days after symptom onset ([@bib11], [@bib28]). Interestingly, the plasma from SARS-CoV-2-infected patients could also cross-react with the SARS-CoV S ectodomain (p = 8e−06, two-tailed t test) and the SARS-CoV RBD (p = 0.048, two-tailed t test) ([Figure 1](#fig1){ref-type="fig"}B). Nevertheless, only five of the samples from the SARS-CoV-2-infected patients (patient nos. 4, 6, 11, 14, and 15) had convincing antibody-binding responses to the SARS-CoV RBD (optical density 450 \[OD~450~\] \> 0.5; [Figure 1](#fig1){ref-type="fig"}B; [Table S1](#mmc1){ref-type="supplementary-material"}). However, all samples were collected within 22 days after symptom onset, which is fairly early in the maturation of the humoral immune response, when antibody titers are still increasing ([@bib11]). It is possible that more samples would have detectable cross-reactive binding to the SARS-CoV RBD if collected at later time points. In summary, these results indicate that the cross-reactive antibody response to the S protein after SARS-CoV-2 infection targets both RBD and non-RBD regions. Consistent with that observation, reactivity of the plasma from SARS-CoV-2-infected patients could be detected with the S2 subunit of SARS-CoV-2 (p = 2e−4, two-tailed t test; [Figure 1](#fig1){ref-type="fig"}B).

We also analyzed seven heparin-anticoagulated, convalescent (3--6 months after infection) plasma samples from SARS-CoV-infected patients. Similar to that observed in plasma samples from SARS-CoV-2-infected patients, cross-reactivity in binding could be detected ([Figure 1](#fig1){ref-type="fig"}B). As compared with the plasma from healthy donors, SARS-CoV-infected patients have significant cross-reactivity in binding to the SARS-CoV-2 spike (p = 0.03, two-tailed t test), RBD (p = 0.03, two-tailed t test), and the S2 subunit (p = 0.007, two-tailed t test). These findings show that cross-reactivity in binding is common between SARS-CoV and SARS-CoV-2 infections in both directions. Of note, our recombinant S ectodomains of both SARS-CoV-2 and SARS-CoV contained several mutations to stabilize the prefusion conformation (see [STAR Methods](#sec4){ref-type="sec"}), which should not affect most neutralizing epitopes.

Patient Samples Show Limited Cross-Neutralization {#sec2.2}
-------------------------------------------------

We next tested the neutralization activity of these plasma samples from SARS-CoV-2-infected patients. Except for four plasma samples that came from patients who had fewer than 12 days after symptom onset (patient nos. 1, 2, 9, and 13) with concomitantly low reactivity to both SARS-CoV-2 S ectodomain and RBD (OD~450~ \< 0.1), all other plasma samples could neutralize the SARS-CoV-2 virus with titers ranging from 1:40 to 1:640 ([Figure 1](#fig1){ref-type="fig"}C; [Table S1](#mmc1){ref-type="supplementary-material"}). However, only one plasma sample could cross-neutralize SARS-CoV, with very low neutralization activity (1:10). In fact, that cross-neutralizing plasma sample had the strongest reactivity in binding against SARS-CoV S ectodomain among all 15 patient samples, although its binding activity against SARS-CoV RBD was not the strongest ([Table S1](#mmc1){ref-type="supplementary-material"}).

Similarly, although five of the seven plasma samples from SARS-CoV-convalescent patients could neutralize SARS-CoV with titers ranging from 1:40 to 1:320, none could cross-neutralize SARS-CoV-2 ([Figure 1](#fig1){ref-type="fig"}C). These results show that although cross-reactivity in binding is common between plasma from SARS-CoV-2 and SARS-CoV-infected patients, cross-neutralization activity may be rare.

Cross-Reactivity in Mouse Infection and Immunization {#sec2.3}
----------------------------------------------------

It is unclear how immune history to corona- and other viruses, which is likely to vary among individuals, influences the antibody response to SARS-CoV-2 and SARS-CoV infection. We, therefore, investigated the cross-reactivity of antibody responses to SARS-CoV-2 and SARS-CoV in mice with no such immune history. Live viruses were inoculated into mice either intranasally (infection) or through intraperitoneal injection with adjuvant (immunization). We have previously shown that intraperitoneal injection of live influenza virus together with adjuvant can induce detectable immune response in mice ([@bib38]). Although SARS-CoV can replicate and elicit antibody response in wild-type mice ([@bib41]), SARS-CoV-2 cannot ([@bib3]). As a result, intraperitoneal injection of SARS-CoV-2 virus with adjuvant provided an alternative way to study the immune response of SARS-CoV-2 virus *in vivo*.

The antibody responses of plasma collected from mice infected or immunized with SARS-CoV-2 or SARS-CoV (n = 5 or 6 per experimental and control groups) were analyzed by ELISA. Plasma from mice with mock immunization with a genetically more-distant betacoronavirus, coronavirus OC43-CoV, PBS, or adjuvant was used as the negative controls ([Figures 2](#fig2){ref-type="fig"} A--2D). As compared with controls, plasma from mice immunized with SARS-CoV-2 virus had significant binding to its autologous S ectodomain (p \< 0.002, two-tailed t test; [Figure 2](#fig2){ref-type="fig"}A) and RBD (p \< 1e−4, two-tailed t test; [Figure 2](#fig2){ref-type="fig"}B). Similarly, plasma from mice immunized with SARS-CoV virus had significant binding to its autologous S ectodomain (p \< 2e−7, two-tailed t test; [Figure 2](#fig2){ref-type="fig"}C) and RBD (p \< 6e−6, two-tailed t test; [Figure 2](#fig2){ref-type="fig"}D). In addition, plasma from mice immunized with SARS-CoV S ectodomain could react to its autologous RBD (p \< 0.02, two-tailed t test; [Figure 2](#fig2){ref-type="fig"}D). However, although plasma from mice infected with SARS-CoV virus could react with its autologous S ectodomain (p \< 8e−6, two-tailed t test; [Figure 2](#fig2){ref-type="fig"}C) and RBD (p \< 2e−5, two-tailed t test; [Figure 2](#fig2){ref-type="fig"}D), the reactivity of plasma from mice infected with SARS-CoV-2 virus to its autologous S ectodomain and RBD could not be observed in this assay (p \> 0.28, two-tailed t test; [Figures 2](#fig2){ref-type="fig"}A and 2B). As expected, an antibody response from SARS-CoV-2-infected wild-type mice was not detected because of the inability of SARS-CoV-2 to replicate in wild-type mice ([@bib3]).Figure 2Mouse Serological Response to SARS-CoV-2 and SARS-CoV(A--D) Binding of plasma from OC43-CoV-immunized mice, SARS-CoV-immunized mice, SARS-CoV-infected mice, and mock-immunized mice against (A) SARS-CoV-2 spike protein, (B) SARS-CoV-2 RBD protein, (C) SARS-CoV spike protein, and (D) SARS-CoV RBD protein were measured by ELISA. Because both SARS-CoV spike protein and SARS-CoV-2 spike contained a C-terminal foldon domain, binding of plasma from mice immunized with the SARS-CoV spike protein plasma was not tested against spike proteins from SARS-CoV and SARS-CoV-2. The mean OD~450~ values calculated after testing each plasma sample in triplicate are shown.(E and F) Neutralization activities of plasma from mice infected or immunized by SARS-CoV-2 or SARS-CoV to (E) SARS-CoV-2 virus or (F) SARS-CoV virus were measured. Dashed line represents the lower detection limit. Black lines indicate means ± SD. The value from each dot in the figure was taken by the means of two replicates in the same assay.

Interestingly, we observed some cross-reactivity of plasma from SARS-CoV-2-immunized mice to both the SARS-CoV S ectodomain (p \< 4e−5, two-tailed t test; [Figure 2](#fig2){ref-type="fig"}C) and the SARS-CoV RBD (p \< 0.006, two-tailed t test; [Figure 2](#fig2){ref-type="fig"}D), as well as plasma from SARS-CoV-infected mice to the SARS-CoV-2 S ectodomain (p \< 0.005, two-tailed t test; [Figure 2](#fig2){ref-type="fig"}A) but not to the RBD. Of note, the absence of detectable binding of plasma from SARS-CoV-infected mice to SARS-CoV-2 RBD ([Figure 2](#fig2){ref-type="fig"}B) could be due to the overall weak cross-reactive antibody response to SARS-CoV-2, as indicated by the relatively weak binding to the CoV-2 S ectodomain (OD~450~ ranges from 0.3 to 0.8; [Figure 2](#fig2){ref-type="fig"}A). It is possible that binding of plasma from SARS-CoV-infected mice to SARS-CoV-2 RBD would become detectable if the overall antibody response increases. Similarly, the lack of detectable binding of plasma from SARS-CoV-immunized mice to either SARS-CoV-2 S ectodomain or RBD (p \> 0.5, two-tailed t test) could be due to the overall low antibody response. Despite the presence of cross-reactivity in binding, cross-neutralization activity was not detected in any of the mouse plasma samples ([Figures 2](#fig2){ref-type="fig"}E and 2F), corroborating our findings from human patients.

Discussion {#sec3}
==========

The work shows that antibody responses in the SARS-CoV-2-infected patient cohort are generated to both S protein and RBD in most patients. Furthermore, cross-reactive antigen binding with SARS-CoV can be detected in those plasma samples as well as in mice studies. Those cross-reactive antibody responses target both the RBD and non-RBD regions. Although higher-sequence conservation is found between the S2 subunits of SARS-CoV-2 and SARS-CoV (90% amino-acid sequence identity) as compared with that of their RBDs (73% amino-acid sequence identity), some SARS-CoV-2-infected patients were able to produce cross-reactive antibody binding to SARS-CoV RBD. Similarly, a human antibody CR3022 that neutralizes SARS-CoV ([@bib26]) has been reported to also bind to the RBD of SARS-CoV-2 ([@bib27]) by targeting a conserved epitope that is only accessible when at least two RBDs on the trimeric S protein are in the "up" conformation ([@bib43]). Furthermore, a more recent study has discovered and characterized antibody S309 from memory B cells of a SARS-CoV survivor that cross-neutralizes SARS-CoV and SARS-CoV-2 and targets another conserved epitope that is distinct from the CR3022 epitope ([@bib23]).

Although cross-reactive antibody-binding responses to both SARS-CoV-2 and SARS-CoV S proteins appear to be relatively common in this cohort, cross-neutralizing responses may be rare. Only one out of 15 SARS-CoV-2-infected patients was able to generate a cross-neutralizing response to both SARS-CoV-2 and SARS-CoV viruses, and that cross-reactive response was very weak. Therefore, it is possible that only a subset of the cross-reactive binding epitopes is a bona fide neutralizing epitope. This notion is also supported by our recent study, which showed that the cross-reactive antibody CR3022 could not neutralize SARS-CoV-2, despite its relatively strong binding ([@bib43]). Future studies need to investigate whether these non-neutralizing antibody responses can confer *in vivo* protection despite the lack of *in vitro* neutralization activity ([@bib43]), which have been observed in some non-neutralizing antibodies to other viruses ([@bib1], [@bib2], [@bib4], [@bib5], [@bib7], [@bib12], [@bib16], [@bib22], [@bib34]). In contrast, non-neutralizing antibody responses can also lead to antibody-dependent enhancement (ADE) of infection as reported in other coronaviruses ([@bib29], [@bib33], [@bib35]). Whether ADE has a role in SARS-CoV-2 infection will need to be carefully examined because of its potential adverse effect in vaccination ([@bib29]). It will also be important to determine the role of RBD and S2 antibodies, as well as other domains, in neutralization. Competition experiments by preincubating the virus with autologous and heterologous RBD or S2 proteins before incubation with the plasma in neutralization assay may help to further understand mechanisms of cross-reactivity.

SARS-CoV-2 is the third newly emerged coronavirus to cause outbreaks (along with SARS-CoV and MERS-CoV) in the past two decades. Because coronavirus outbreak are likely to continue to pose global health risks in the future ([@bib19], [@bib20]), the possibility of developing a cross-protective vaccine against multiple coronaviruses has been considered. Identification of cross-protective epitopes on the coronavirus S protein will be important for the development of a more universal coronavirus vaccine analogous to those currently in development for influenza virus ([@bib9], [@bib46]). Our findings, albeit limited at present, would suggest that such broadly cross-neutralizing epitopes to coronaviruses might not be that commonly targeted by the human immune repertoire. Moving forward, monoclonal antibody discovery and characterization will be crucial to development of a SARS-CoV-2 vaccine in the short term as well as a cross-protective coronavirus vaccine in the long term.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Biological Samples**Plasma from SARS-CoV-2 patientsHospital Authority of Hong KongN/APlasma from SARS-CoV survivorsHospital Authority of Hong KongN/APlasma from healthy donorsHong Kong Red CrossN/A**Chemicals and Recombinant Proteins**S2 extracellular domain of SARS-CoV-2Sino Biological40590-V08BDpnINew England BiolabsR0176LTrypsinNew England BiolabsP8101SPBSCorning21-040-CMRBovine Serum Albumin (BSA)Sigma-AldrichA9418Tween 20Fisher ScientificBP337-500AMDEX sheep anti-human IgG-HRPGE HealthcareRPN4101AMDEX sheep anti-mouse IgG-HRPGE HealthcareRPN4201KetamineAlfasan International BV1711347-09XylazineAlfasan International BV1804117-11**Critical Commercial Assays**In-Fusion HD Cloning KitTakara639647KOD Hot Start DNA PolymeraseEMD Millipore71086-3PCR Clean-Up and Gel Extraction KitClontech Laboratories740609.250QIAprep Spin Miniprep KitQIAGEN27106**Cell Lines**Sf9 cellsATCCCRL-1711High Five cellsThermo Fisher ScientificB85502Vero cellsATCCCCL-81Vero E6 cellsATCCCCL-1586**Deposited Data**SARS-CoV-2 spike protein sequenceNCBI Reference Sequence[YP_009724390.1](ncbi-p:YP_009724390.1){#intref0010}SARS-CoV spike protein sequenceGenBank[ABF65836.1](ncbi-p:ABF65836.1){#intref0015}**Oligonucleotides**Primers for cloningIntegrated DNA TechnologiesN/A**Recombinant DNA**pFastBac-SARS-CoV-2 spike ectodomainThis studyN/ApFastBac-SARS-CoV spike ectodomainThis studyN/ApFastBac-SARS-CoV-2 RBDThis studyN/ApFastBac-SARS-CoV RBDThis studyN/A**Software and Algorithms**R<https://www.r-project.org>N/A**Other**HyClone insect cell culture mediumGE HealthcareSH30280.03DMEMThermo Fisher Scientific11965-092AddavaxInvivoGenvac-adx-10Nunc MaxiSorp ELISA plateNunc MaxiSorp ELISA plate44-2404-21Phosphate-buffered saline (PBS)Thermo Fisher Scientific14040133Ni-NTA SuperflowQIAGEN30450FuGENE HDPromegaE2311DH10Bac competent cellsThermo Fisher Scientific10361012

Resource Availability {#sec4.2}
---------------------

### Lead contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Chris K. P. Mok (<ch02mkp@hku.hk>).

### Materials availability {#sec4.2.2}

All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

### Data and software availability {#sec4.2.3}

This study did not generate any unique datasets or code.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

Vero and Vero E6 cells were maintained in DMEM medium supplemented with 10% fetal bovine serum (FBS), and 100 U mL^-1^ of Penicillin-Streptomycin. Sf9 cells (*Spodoptera frugiperda* ovarian cells, female) and High Five cells (*Trichoplusia ni* ovarian cells, female) were maintained in HyClone insect cell culture medium.

Patient-derived SARS-CoV-2 (BetaCoV/Hong Kong/VM20001061/2020 \[KH1\]) and SARS-CoV (strain HK39849, SCoV) were passaged in Vero-E6 cells and the virus stock was aliquoted and titrated to determine tissue culture infection dose 50% (TCID~50~) in Vero-E6 cells. The neutralization experiments were carried out in a Bio-safety level 3 (BSL-3) facility at the School of Public Health, LKS Faculty of Medicine, The University of Hong Kong.

Patients with RT-PCR confirmed COVID-19 disease at the Infectious Disease Centre of the Princess Margaret Hospital, Hong Kong, were invited to participate in the study after providing informed consent. The age and gender of the patients are listed in [Table S1](#mmc1){ref-type="supplementary-material"}. The study was approved by the institutional review board of the Hong Kong West Cluster of the Hospital Authority of Hong Kong (approval number: UW20-169). 6-8 weeks old male BALB/c mice were used in this study. The experiments were conducted in The University of Hong Kong Biosafety Level 3 (BSL3) facility. The study protocol was carried out in strict accordance with the recommendations and was approved by the Committee on the Use of Live Animals in Teaching and Research of the University of Hong Kong (CULATR 4533-17).

Method Details {#sec4.4}
--------------

### Collection of plasma samples {#sec4.4.1}

Specimens of heparinized blood were collected from the patients, and the plasma were separated and stored at −80°C until use. The plasma was heat inactivated at 56°C for 30 minutes before use. The plasma samples from patients with SARS-CoV infection were obtained from the bio-repository of specimens stored from patients following the SARS outbreak in 2003.

### Protein expression and purification {#sec4.4.2}

Ectodomain (residues 14-1195) with K968P/V969P mutations and RBD (residues: 306-527) of the SARS-CoV spike (S) protein (GenBank: [ABF65836.1](ncbi-p:ABF65836.1){#intref0030}), as well as the ectodomain (residues 14-1213) with R682G/R683G/R685G/K986P/V987P mutations and RBD (residues 319-541) of the SARS-CoV-2 spike protein (GenBank: QHD43416.1) were cloned into a customized pFastBac vector ([@bib8]). K968P/V969P were stabilizing mutations inserted into the SARS-CoV spike protein ([@bib15]) and the corresponding K986P/V987P mutations in the SARS-CoV-2 spike protein were intended to have the same stabilizing effect due to sequence similarity. R682G/R683G/R685G mutations in the SARS-CoV-2 spike protein were designed to knock-out the furin cleavage site that is a novel addition to this particular coronavirus compared to related sequences in bats and pangolins, as well as other coronaviruses ([@bib36]). Furin cleavage site knockout mutations can stabilize the prefusion conformation of the coronavirus spike ectodomain by preventing furin processing without affecting its overall structure ([@bib14], [@bib31]). In fact, both K986P/V987P mutations and furin cleavage site knockout mutations were present in the recent recombinant SARS-CoV-2 spike ectodomain constructs ([@bib32], [@bib37]). The spike ectodomain constructs were fused with an N-terminal gp67 signal peptide and a C-terminal BirA biotinylation site, thrombin cleavage site, trimerization domain, and His~6~ tag. The RBD constructs were fused with an N-terminal gp67 signal peptide and a C-terminal His~6~ tag. Recombinant bacmid DNA was generated using the Bac-to-Bac system (Life Technologies). Baculovirus was generated by transfecting purified bacmid DNA into Sf9 cells using FuGENE HD (Promega), and subsequently used to infect suspension cultures of High Five cells (Life Technologies) at an MOI of 5 to 10. Infected High Five cells were incubated at 28 °C with shaking at 110 rpm for 72 h for protein expression. The supernatant was then concentrated using a Centramate cassette (10 kDa MW cutoff for RBD and 30 kDa MW cutoff for spike protein, Pall Corporation). Spike ectodomain and RBD proteins were purified by Ni-NTA ([Figure S2](#mmc1){ref-type="supplementary-material"}), followed by size exclusion chromatography, and then buffer exchanged into PBS. The S2 extracellular domain of SARS-CoV-2 was purchased from Sino Biological, China.

### Mouse immunization {#sec4.4.3}

The BALB/c mice were immunized with 10^5^ pfu of SARS-CoV, SARS-CoV-2, HCoV-OC43 or 15 μg of SARS-CoV spike protein in 150 μL PBS together with 50 μL Addavax (MF59-like squalene adjuvant from InvivoGen) through intraperitoneally injection (i.p.). For the control group, BALB/c mice were injected intraperitoneally (i.p.) with 50 μL Addavax plus 150 μL PBS, or 200 μL PBS only. The plasma samples were collected on day 14 post-vaccination using heparin tubes.

### Mouse infection {#sec4.4.4}

6-8 weeks BALB/c mice were anesthetized with Ketamine and Xylazine, and infected intranasally (i.n.) with 10^5^ pfu of patient-derived SARS-CoV or SARS-CoV-2 diluted in 25 μL PBS. Mouse plasma samples were collected on day 14 post-infection using heparin tubes. The experiments were conducted in the University of Hong Kong Biosafety Level 3 (BSL3) facility.

### ELISA binding assay {#sec4.4.5}

A 96-well enzyme-linked immunosorbent assay (ELISA) plate (Nunc MaxiSorp, Thermo Fisher Scientific) was first coated overnight with 100 ng per well of purified recombinant protein in PBS buffer. To substrate the background noise caused by the unspecific binding of antibodies from the samples, serum-specific background noise (SSBN) normalization approach was used ([@bib21]). In brief, an additional plate was coated overnight with PBS buffer only. The plates coated with either purified recombinant protein or PBS were then blocked with PBS containing 5% non-fat milk powder at room temperature for 2 hours. Each mouse plasma sample was 1:10 diluted and human sample was serially diluted from 1:100 to 1:12800 in PBS. Each sample was then added into the ELISA plates that were coated with purified recombinant protein or PBS buffer respectively for 2-hour incubation at 37°C. After extensive washing with PBS containing 0.1% Tween 20, each well in the plate was further incubated with the HRP-sheep anti-mouse IgG or anti-human IgG secondary antibody (1:5000, GE Healthcare) for 1 hour at 37°C. The ELISA plates were then washed five times with PBS containing 0.1% Tween 20. Subsequently, 50 μL of each solution A and B (R&D Systems) was added into each well. After 15 minutes incubation, the reaction was stopped by adding 50 μL of 2 M H~2~SO~4~ solution and analyzed on a Sunrise (Tecan) absorbance microplate reader at 450 nm wavelength. The normalized results were obtained by calculating the difference between the OD of the purified recombinant protein-coated well and the PBS-coated well.

### Microneutralization assay {#sec4.4.6}

Plasma samples were diluted in serial two-fold dilutions commencing with a dilution of 1:10, and mixed with equal volumes of SARS-CoV or SARS-CoV-2 at a dose of 200 tissue culture infective doses 50% (TCID~50~) determined by Vero and Vero E6 cells respectively. After 1 h of incubation at 37°C, 35 μL of the virus-serum mixture was added in quadruplicate to Vero or Vero E6 cell monolayers in 96-well microtiter plates. After 1 h of adsorption, the virus-serum mixture was removed and replaced with 150ul of virus growth medium in each well. The plates were incubated for 3 days at 37°C in 5% CO~2~ in a humidified incubator. Cytopathic effect was observed at day 3 post-inoculation. The highest plasma dilution protecting 50% of the replicate wells was denoted as the neutralizing antibody titer. A virus back-titration of the input virus was included in each batch of tests.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

The p values reported were computed by the paired Student's t test using the R software package.
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